AstraZeneca PLC Release: New European Society of Cardiology Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients With ST-Elevation

Published: Aug 28, 2012

LONDON--(BUSINESS WIRE)--AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised “Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)” guidelines. Ticagrelor is known as BRILIQUE in the European Union and BRILINTA elsewhere.

Back to news